Original Research Article

Patterns of antihypertensive drug distribution of patients with hypertensive diabetes mellitus: A Hospital based observational study

Authors

Dr Yasmin Sultana Rahman¹, Dr N. P. Yadav²

¹Post Graduate Trainee, Department of Pharmacology, Katihar Medical College, Katihar, Bihar, India
²Principle & Professor, Department of Pharmacology, Katihar Medical College, Katihar, Bihar, India

Corresponding Author

Dr Yasmin Sultana Rahman
Post Graduate Trainee, Department of Pharmacology, Katihar Medical College, Katihar, Bihar, India
Ph: +91 8002736323, Email: drysrahmankmc@gmail.com

Abstract

Objectives: This present study was to evaluate the pattern of antihypertensive drug distribution as monotherapy, combination therapy and fixed dose combination of patients with hypertensive diabetes mellitus.

Methodology: A total of 100 patients of hypertensive diabetes mellitus were enrolled in this study. A detail history, complete assessment and relevant investigation were taken to all patients. Pattern of drug prescription was monotherapy, combination therapy and fixed dose combination.

Results: Data was analyzed by using simple statistical methods with the help of MS-Office software. Conclusions: Patients of hypertensive diabetes mellitus was commonly seen in beyond 4th decades of life. Calcium channel blockers (amlodipine) and ACE inhibitors (Enalapril, ramipiril, lisinopril, levipril) were greatly prescribed in patients of hypertensive diabetes mellitus as monotherapy. AT II blocker with diuretics, ACE inhibitors with diuretics and β blocker with Calcium channel blocker were commonly used as combination therapy. And as a fixed dose combination therapy calcium channel blockers with angiotensine II receptor blocker and β blockers with diuretics were prescribed in majorities of patients with hypertensive diabetes mellitus. In mild to moderate HTN, the first line of treatment was lifestyle modification, i.e., weight control, low fat anti-atherogenic diet, salt restriction, reduction in alcohol intake, discontinuation of smoking, and some regimens of physical activity.

Keywords: Hypertension, Hypertensive diabetes mellitus, Antihypertensive drug prescription.

Introduction

Management of hypertension in diabetics demands special attention, more so in Indian scenario. Higher prevalence of hypertension (HTN) amongst diabetics in India has been reported since 1985.[¹] Review on the subject by Das in 1995 (on Indian data) had revealed the prevalence to be as variable as 7 per cent in Cuttack to 30.9 per cent at Sevagram[²]. Further, there was a variable difference between IDDM (Type-1) and NIDDM (Type-2) i.e., 10 versus 32 per cent respectively in diabetics from Mumbai2. Studies from Manipal revealed about 40 per cent diabetics to be hypertensive[³]. Such higher prevalence of HTN could partly be due to better assessment in diabetics but most likely on par
with change of lifestyle and increase in the prevalence of noncommunicable diseases in rapidly growing economies.\textsuperscript{[4]}

India currently has 40.9 million diabetic patients and it is expected to rise to 69.9 million by 2025 unless urgent and effective preventive steps are taken.\textsuperscript{[5]} One and half billion people will suffer from hypertension and 300 million will suffer from diabetes by 2025.\textsuperscript{[6,7]}

Prevalence of hypertension is 60\% in type 2 DM.\textsuperscript{[8]} Patients with T2DM has two fold higher chances of suffering from hypertension in comparison to age match subjects without diabetes.\textsuperscript{[9]} Hypertension has been shown as a major risk factor not only for the development of diabetes but also for the development of micro and macro vascular complications like neuropathy, nephropathy, retinopathy, coronary artery disease, stroke, Peripheral Vascular Disease (PVD) in diabetic patients.\textsuperscript{[10]}

Aim of our study was to evaluate the prescribing pattern of antihypertensive drugs for the management of hypertensive diabetes mellitus patients to achieve minimum complication.

**Materials & Methods**

This present study was conducted in department of Pharmacology with the collaboration of department of Medicine, Katihar Medical College and Hospital, Katihar, Bihar, India during a period from February 2017 to October 2017.

A total of 100 patients of hypertension with diabetes mellitus of age group less than 30 years to greater than 75 years were enrolled in this study. Entire subjects signed an informed consent approved by institutional ethical committee of Katihar Medical College, Katihar, Bihar India was sought.

**Methods**

Data was collected by using random sampling methods. Inclusion criteria of this study was the patients of hypertension with diabetes mellitus taking treatment from department of Medicine, Katihar Medical College and Hospital, Katihar, Bihar. Patients of diabetes mellitus with hypertension who were suffering from any other diseases like lungs diseases, cardiac diseases, metases, e.t.c were excluded from this study. Monotherapy, combination therapy and fixed dose combination were used as patterns of drug prescription in patients of hypertension with diabetes mellitus.

**Statistical Analysis**

Data was analyzed by using simple statistical methods with the help of MS-Office software.

**Observations**

This study was conducted in department of Pharmacology, Katihar Medical College, Katihar, Bihar, India.

In this present study, we were enrolled the patients with age less than 30 years to age greater than 75 years. Out of total 100 patients, 60 patients were males and 40 patients were females. Male and female ratio was 3:2.

**Table. 1 Age wise distribution of patients with hypertensive diabetes mellitus.**

| Age(Years) | No. of patients | Percentage |
|------------|-----------------|------------|
| < 30 years | 3               | 3\%        |
| 31-45      | 10              | 10\%       |
| 46-60      | 45              | 45\%       |
| 61-75      | 30              | 30\%       |
| > 75       | 12              | 12\%       |
| Total      | 100             | 100\%      |

Majorities of cases 45(45\%) of diabetes with hypertension were in age group of 46 years to 60 years.

**Table.2. Categories wise drug distribution in hypertensive diabetes mellitus patients.**

| Categories of drugs | No. of cases | Percentage |
|---------------------|--------------|------------|
| Calcium channel blockers | 24           | 24\%       |
| amlodipine          |              |            |
| ACE inhibitors      | 20           | 20\%       |
| (Enalapril, ramipril, lisinopril, levipril) | | |
| Diuretics ( furesamide, torsemide) | 16 | 16\% |
| β blockers (atenolol) | 10           | 10\%       |
| K+ opener (nicorandril) | 3            | 3\%        |

In this study, we were found that calcium channel blockers amlodipine was prescribed in majorities of diabetes mellitus with hypertension patients.
24(24%) as a monotherapy. ACE inhibitor was prescribed in 20 (20%) diabetes with hypertension patients.

**Table 3.** Combination of drugs distribution

| Category of drugs | No. of cases | Percentage |
|-------------------|--------------|------------|
| AT II blocker + diuretics | 26 | 26% |
| ACE inhibitors + diuretics | 10 | 10% |
| β blocker + Calcium channel blocker | 10 | 10% |
| Calcium channel blocker + ACE inhibitor | 7 | 7% |
| AT II blocker + ACE inhibitors | 7 | 7% |
| Calcium channel blocker + diuretics | 7 | 7% |
| B blocker + AT II blocker | 7 | 7% |

In this present study, combination of antihypertensive drugs was also used in the cases of diabetic mellitus.

AT II blockers with diuretics was prescribed by the Physicians in maximum number of cases 26(26%). ACE inhibitors with diuretics and B blocker with calcium channel blocker were prescribed in 10(10%) patients of diabetes mellitus. Calcium channel blocker with ACE inhibitor, AT II blocker with ACE inhibitor and calcium channel blocker with diuretics were prescribed in 7(7%) patients of diabetes mellitus.

**Table 4.** Fixed dose combination of drug distribution in hypertensive diabetes mellitus patients

| Categories of drugs | No. of cases | Percentage |
|---------------------|--------------|------------|
| β blockers + diuretics | 28 | 28% |
| Calcium channel blockers + angiotensin II receptor blocker | 46 | 46% |
| ACE inhibitors + diuretics | 19 | 19% |
| AT II blocker + diuretics | 10 | 10% |

In this present study, calcium channel blockers with angiotensin II receptor blocker were prescribed in majorities of patients 46(46%) of diabetes with hypertension as a fixed dose combination.

**Table 5.** Aspirine distribution in hypertensive diabetes mellitus patients

| Drugs             | No. of cases | Percentage |
|-------------------|--------------|------------|
| Aspirine used     | 5            | 5%         |
| Aspirine not prescribed | 95     | 95%        |

Aspirine was prescribed by Physician in only 5(5%) patients of hypertension with diabetes mellitus.

**Table 6.** Lipid lowering drugs (LLD) distributions in hypertensive diabetes mellitus patients

| Drugs                  | No. of cases | Percentage |
|------------------------|--------------|------------|
| LLD prescribed         | 14           | 14%        |
| LLD not prescribed     | 86           | 86%        |

In this present study, lipid lowering drugs was prescribed by the Physicians in 14(14%) of patients of hypertension with diabetes mellitus

**Discussion**

Hypertension and Diabetes are life style disease and are the major burden of global Health due to complications.

Hypertension has a major risk factor not only for the development of diabetes but also for the development of micro and macro vascular complications like neuropathy, nephropathy, retinopathy, coronary artery disease, stroke, Peripheral Vascular Disease (PVD) in diabetic patients. The benefits of Blood Pressure (BP) control in diabetic patients exceed the benefits of tight glycemic control and vital to the prevent and retard progression of both microvascular and macrovascular complications of hyperglycemias.\(^{[11]}\) Therefore, all of the hypertension management guidelines, that is, eighth report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-2013 (JNC-8),\(^{[12]}\) American Diabetes association (ADA) 2014\(^{[13]}\) and European Society of Hypertension (ESH 2013)\(^{[14]}\) focused aggressively on Blood Pressure (BP) control in diabetic patient to below 140/80-90 mmHg. JNC 8 recommended target of diastolic BP <90 mmHg and ESC 2013 recommended <85 mmHg. But ADA recommended target of DBP <80 mmHg. There are limited data from India regarding physician’s choices of anti-hypertensive therapies for a patient with diabetes in single- and multiple-drug based regimens.\(^{[10]}\) Khrime D, et al. (2015)\(^{[10]}\) were conducted a study of utilisation of antihypertensive drugs for the patients of hypertensive diabetes mellitus. They
were enrolled 223 patients with age group of 18-86 years and in their study male and female ratio was 1.18: 1.

In our present study, we were enrolled a total of 100 patients with age group less than 18 years to greater than 30 years. Male and female ratio was 3:2. Majorities of cases 45(45%) of hypertensive diabetes mellitus were belonged in age group of 46 years to 60 years.

In diabetic patients, particularly those with mild to moderate HTN, the first line of treatment includes lifestyle modification, i.e., weight control, low fat anti-atherogenic diet, salt restriction, reduction in alcohol intake, discontinuation of smoking, and supervised regimens of physical activity. The next step would be administration of antihypertensive drugs. Five classes of drugs are considered to be effective for monotherapy. Diuretics, beta-blockers, calcium channel blocker, alpha 1 adrenergic blockers, ACE-inhibitors, and likely angiotensin-receptor antagonists are the armamentarium of first line drugs available for use in India. In the absence of randomised controlled large scale clinical trials on the various classes of antihypertensive agents in diabetic patients with HTN, the choice of treatment is based on our understanding of the pathophysiology of HTN in diabetics and known pharmacological action as well as side-effects of the drug to be administered.[4]

Our study was support the findings of Khriime D, et al. (2015).[10] In their study monotherapy was needed in 46.18% (n =103) patients and dual therapy was required in 32.73% (n=73) patients. Thirty nine patients (17.48%) were on triple drug therapy and eight patients (8.07%) were on quadruple drug therapy.

Use of multiple drugs in combinations is being increasingly recognized as critical to control hypertension in patients with diabetes. Fixed-dose combination (FDC) therapies offer a means to simplify complex treatment regimens, and have several advantages that help patients reach their glycaemic goals. Recently, several large clinical trials demonstrated that most patients with hypertension can achieve and sustain adequate blood pressure control only with the use of multiple antihypertensive drugs. Initiating drug therapy with a diuretic, either alone or in combination with an agent from another drug class apparently provides the best outcomes for hypertension management as per the JNC VII and JNC VIII guidelines.

In our study, calcium channel blockers amlodipine was prescribed in majorities of hypertensive diabetes mellitus patients 24(24%) as a monotherapy. ACE inhibitor was prescribed in 20 (20%) patients. AT II blockers with diuretics was prescribed by the Physicians in maximum number of cases 26(26%). ACE inhibitors with diuretics and B blocker with calcium channel blocker were prescribed in 10(10%) patients of diabetes mellitus. Calcium channel blocker with ACE inhibitor, AT II blocker with ACE inhibitor and calcium channel blocker with diuretics were prescribed in 7(7%) patients of diabetes mellitus. Calcium channel blockers with angiotensine II receptor blocker were prescribed in majorities of patients 46(46%) of diabetes with hypertension as a fixed dose combination.

The SHEP study[15] using low dose diuretics, beta blockers, calcium channel blockers, ACE–inhibitors and the SYST – EUR study[16] using calcium channel blockers and ACE – inhibitors with diuretics as reserve, have shown beneficial effects of BP control as concluded by extension of UKPD study group alluded to above. It is to be noted that both SHEP and SYST-EUR Study recruited diabetic hypertensives also for the trials. The International Diabetic Federation Consensus guidelines[17] have anticipated reduction in stroke morbidity and mortality, heart failure morbidity and mortality, in CAD events and reduction in progression of renal disease including diabetic nephropathy by tight control of hypertension in DM. Reduced left ventricular hypertrophy, a marker for CAD and HF was anticipated as a relevant surrogate outcome. The above list does not include the benefit of management of malignant HTN.
In the UKPDS epidemiological study, each 10 mm Hg decrease in the mean systolic BP was associated with reduction in risk of 12% for any complication related to DM, 15% for deaths related to DM, 11% for myocardial infarction, and 13% for microvascular complications.\(^{[35]}\)

The UK PDS suggests that blood pressure reduction itself may be more important than the measures used to achieve it, but ACE inhibitors were better tolerated. Systolic hypertension in the elderly (SHEP) trial, Hypertension Optimal Study (HOTstudy)\(^{[18]}\) and SYST-EUR study used β-Blockers and/or diuretics and many of the subjects included in the trials were diabetic. All these trials demonstrated beneficial effects of treatment in reducing cardiovascular mortality and morbidity.\(^{[19]}\) Low dose thiazides, beta-blockers, ACE inhibitors, dihydropyridine calcium channel blockers (long acting) have all shown benefits in type-2 DM\(^{[20]}\). That both older (beta blockers, diuretics) and newer drugs (ACE inhibitors, calcium channel blockers, alpha-blockers, and angiotension-II receptor, blockers) have equal efficacy have been proved by various trials. They all reduce mortality and morbidity of CV events in hypertensives (even those with DM) and they all improve the quality of life\(^{[21,22]}\).

ACE inhibitors have renoprotective effect by reducing intraglomerular pressure. They reduce albuminuria in diabetic nephropathy, reduce rate of renal deterioration, and have no adverse effect on lipids. They minimise adverse metabolic effects of diuretics\(^{[23,24]}\) and may have a specific role if nephropathy is present in type-1 DM\(^{[20]}\). They may potentiate the hypoglycaemic effect of insulin and oral antidiabetic drugs\(^{[20]}\). Irritable cough and very rarely angio-oedema, are the important side effects. Hypoglycaemia, hyperkalaemia, and rise of serum creatinine should be watched. These drugs are contraindicated in bilateral renal artery stenosis, pregnancy, and lactation. Angiotensin-II receptor blockers have many properties similar to those of ACE-inhibitors. As they don’t inhibit the breakdown of bradykinin and other kinins, cough is not a problem with their use\(^{[1]}\). These drugs (losartan potassium, candesartan, valsartan, etc.) should be used with caution in unilateral renal artery stenosis, aortic or mitral valve stenosis and in hypertrophic obstructive cardiomyopathy\(^{[26]}\).

Calcium channel blockers\(^{[27]}\): Only long acting dihydropyridines (nifedipine-retard, amlodipin, lacidipin) are used. Amlodipin does not have negative ionotropic effects and can be used in diabetic hypertensives with heart failure. Calcium channel blockers are also useful in angina, especially Prinzmetal’s angina. Pedal oedema and headache are the side effects: Gingival hyperplasia may occur\(^{[23,20]}\). When data from all comparative trials of using various drugs in almost 5,000 hypertensive diabetics are combined, the lowest mortality rate has been found with calcium channel blocker based therapy\(^{[28]}\).

Combination of ACE inhibitors and ARB reduce retinal and other ocular complications and lower the level of uric acid seen in diabetic nephropathy. This combination reduces both preload and afterload in patients with subclinical or overt hypertensive heart failure. This combination having a low effective dose of both these agents, the chances of dry cough are reduced much more than monotherapy with ACE-inhibitors or A II\(^{[29]}\).

HOT study, Thrombosis Prevention Trial and ALLAHAT Trial have shown that 75 mg aspirin OD reduces major CV events by 15% but not fatal events, in hypertension especially in diabetes. This is indicated in patients aged 50 years or above, if 10 years CAD– risk is ≥ 15%, if serum cholesterol is ≥ 5 mmol/L and if TOD and CCD exist. The incidence of CAD is definitely reduced.\(^{[18,22]}\)

In this present study, Aspirine was prescribed by Physician in only 5(5%) patients of hypertensive diabetes mellitus. And lipid lowering drugs was prescribed in 14(14%) of patients of hypertension with diabetes mellitus.

According to Joint British Recommendation on Prevention of CAD and Scottish Inter-Collegiate Guidelines, statins lower coronary events, stroke and all cause mortality and are safe, simple, and well tolerated. Statins are indicated in diabetic
hypertension up to age 75 years if serum cholesterol is ≥ 5 mmol/L and 10 year CAD risk ≥30% especially if patient is having angina or MI. Statins lower blood pressure also and they correct dyslipidaemia that commonly accompanies DM[28]. Combination therapy may also be more beneficial than monotherapy in reducing the risk of cardiovascular events. In the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial,[30] those who received the combination of amlodipine and fosinopril had fewer cardiovascular events than those who received either drug alone. Bakris et al [31,32] documented that at comparable BP levels the combination of an ACE inhibitor (either lisinopril or trandolapril) and verapamil was more effective than either drug alone in attenuating both albuminuria and the rate of decline in glomerular filtration rate. The use of a combination of an ACE inhibitor and calcium antagonist is strongly recommended to maximally protect the kidney in diabetic hypertensive patients with nephropathy.[33,34]

Conclusions
This present study was concluded that patients of hypertensive diabetes mellitus were commonly seen in age > 45 years. Calcium channel blockers (amlodipine) and ACE inhibitors (Enalapril, ramipril, lisinopril, levipril) were greatly prescribed in patients of hypertensive diabetes mellitus as monotherapy. AT II blocker with diuretics, ACE inhibitors with diuretics and β blocker with Calcium channel blocker were commonly used as combination therapy. And as a fixed dose combination therapy calcium channel blockers with angiotensine II receptor blocker and β blockers with diuretics were prescribed in majorities of patients with hypertensive diabetes mellitus. In mild to moderate HTN, the first line of treatment was lifestyle modification, i.e., weight control, low fat anti-atherogenic diet, salt restriction, reduction in alcohol intake, discontinuation of smoking, and some regimens of physical activity.

References
1. Patel JC. Diabetes and its complications. J Diab Assn Ind 1985; 25: 16-25.
2. Das S. Etiopathogenesis of hypertension in diabetes mellitus. Int J Diab Dev Count 1995; 15: 106-09.
3. Rau NR, Acharya RV, Shah S. Incidence of diabetic complications in newly detected cases of NIDDM. Nova Nordisk Diabetes Update Proceedings 1999, Helath Care Communications, Bangalore 1999; 35-6.
4. Sidhartha Das, Rina Mohanty, UK Patnaik. Management of Hypertension in Diabetes Mellitus. Journal, Indian Academy of Clinical Medicine. 2001; 2: 1.
5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, eds. Diabetes Atlas. International Diabetes Federation. 3rd ed. Brussels, Belgium: International Diabetes Federation; 2006: 15-103.
6. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365 (9455):217-23.
7. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
8. National Institutes of Health. Diabetes in America. In: NIH, eds. National Institutes of Diabetes and Digestive and Kidney Diseases. 2nd ed. Bethesda, MD: NIH Publication; 1995: 95-1468.
9. Miller GJ, Maude GH, Beckles GLA. Incidence of hypertension and non-insulin dependent diabetes mellitus and associated risk factors in a rapidly developing Caribbean community: the St James survey, Trinidad. J Epidemiol Community Health. 1996;50(5):497-504.
10. Khrime D et al. Antihypertensive drug utilization pattern and awareness in diabetic hypertensive patients at tertiary care centre. Int J Res Med Sci. 2015 Feb;3(2):461-465.

11. UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK prospective diabetes study group. BMJ. 1998; 317(7160):703-13.

12. James PA, Oparil S, Carter BL, Cushman WC, Dennison HC, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014;311(17):1809.

13. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34(28):2159-219.

14. American Diabetes Association. Standards of medical care-2014. Diabetes Care. 2014 Jan;37(Suppl 1):S14-80.

15. Curle JD, Pressel SL, Cutler JA et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Programme Co-operative Research Group. JAMA 1996; 276: 1886-92.

16. Tuomilehto J, Rastinyte D, This L, Staessen J, Reduction of mortality and cardiovascular events in older diabetic patients with isolated systolic hypertension in Europe treated with nitrendipine - based anti hypertensive therapy (Sys-Eur-Trial). Diabetes 1998; 47: A54.

17. Hypertension in People with Type 2 Diabetes (non-insulin dependant diabetes) knowledge - based diabetes – specific guidelines, International Diabetes Federation (European Region) on behalf of the St Vincent Declaration Iniciative.

18. Hansson I, Zanchetti A, Carruthers SG et al. For the HOTStudy Group, effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.

19. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetics: double jeopardy. British trials show clear effects of treatment, specially blood pressure reduction. Selections from Br Med J 1999; 14: 984-9.

20. George C, Wood NL, Blenkinsopp et al. Endocrine system, Editors: Mehta DK, Martin J, Donyai Furniss L et al. British National Formulary-38, September Edition, British Medical Association, Tavistock Square, London, WC1H 9JP, UK andthe Royal Pharmaceutical Society of Great Britain, Lambeth High Street, London, SE1 7JN, UK 1999; 69-77, 82-92: 311-15.

21. Arya SN. The problems of hypertension in the elderly. J Indian Med Assoc 2000; 98: 171-4.

22. Lawrence E, Ramsay B, Williams G et al. British Hypertension Society Guidelines for Hypertension Management 1999; Summary. Selections from Br Med J South Asia Edition 1999; 15: 758.

23. Kaplan NM, Lieberman E. Hypertension and Diabetes, Obesity and Dyslipidaemia in Clinical Hypertension, 7th ed, New Delhi B.I. Waverly Pvt. Ltd 1998; 244-7.

24. Hypertension in People with Type 2 Diabetes (non-insulin dependant diabetes) knowledge - based diabetes – specific guidelines, International Diabetes
Federation (European Region) on behalf of the St Vincent Declaration Initiative.

25. Paul B, Sapra B, Maheswari S, Goyal RK. Role of losartan therapy in the management of diabetic hypertension. J Assoc Physicians India 2000; 48: 514-7.

26. Mehta DK Martin J, Jordan B. Macfarlane CR. British National Formulary 43, British Medical Association, Tavistock Square, London WC 1H 9JP, UK, 2002; 43: 95-7.

27. Stanton A. ABCD Study, Calcium channel blockers. Br Med J 1998: 316: 1471-3.

28. Kaplan NM. Treatment of Hypertension: Drugs-Therapy, Hypertension and diabetes. Kaplan NM, Lieberman E, Neal W, Kaplan’s Clinical Hypertension, Eighth Edition, 530 Walnut Street, Philadelphia, PA 19106 USA, Lippincott Williams and Wilkins, 2002; 314.

29. Kumar S. RAAS in diabetes: therapeutic options, Chug S Clinical Medicine Update, New Delhi, South Asia Publishers Pvt Ltd 2002; 5: 93-8.

30. Tatti P, Pahor M, Byington RP, Di Mauro F, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597–603.

31. Bakris GL, Barnhill, Sadler R: Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912–919.

32. Bakris GL, Weir MR, DeQuattroV, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283–1289.

33. Bakris GL, Williams B: Angiotensin converting enzyme inhibitors and calcium antagonists alone or combines: does the progression of diabetic renal disease differ? J Hypertens 1995;13(suppl):S95–S101.

34. Epstein M: The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Ren Fail 1996;18:813–832.

35. SN Arya. Hypertension in Diabetic Patients – Emerging Trends. JIACM 2003; 4(2): 96-102.